Power Hour Headlines: From Fan Suites to Fast Science
DENVER, Colo., Oct 08, 2025 (247marketnews.com)- Here’s your Power Hour watchlist, full of names with fresh catalysts and eyes on the afterhours tape.
VENU (NYSE:VENU) is stealing the spotlight after reporting over $23 million in demand for its Luxe FireSuites over the past 60 days, with $10.7M in August and $12.3M in September. This traction adds real weight to its “fan-first real estate” model, where suite ownership blends live sports access with cash-flowing assets.
Wall Street is catching on: Cenorium Capital (Strong Buy, $22 target), ThinkEquity (Buy, $18), and Northland Securities (raised from $15 to $17) are lining up behind the name. A recently closed $34M institutional raise at ~$12/share, led by ThinkEquity, also solidifies the company’s valuation base.
VENU’s expansion into Dallas, El Paso, and Tulsa suggests further upside potential.
Xenetic Biosciences (NASDAQ:XBIO) is climbing after expanding its R&D partnership with The Scripps Research Institute, aiming to validate its DNase platform (XBIO-015) in new hematologic and solid tumor models. The goal: suppress neutrophil extracellular traps (NETs) that can weaken CAR T therapies, a key immuno-oncology opportunity.
The company is progressing toward its first IND filing, and with only a $0.7M net loss in Q2, it’s running lean as it builds momentum. Expect afterhours eyes on XBIO if more preclinical data drops or any translational milestones are announced.
AlphaTON Capital (NASDAQ:ATON) is rewriting the playbook for biotech funding. In a bold DeSci (Decentralized Science) move, the company, along with its oncology subsidiary Cyncado Therapeutics, plans to tokenize economic rights to its lead mesothelioma candidate, TT-4. The drug, a selective A2B receptor antagonist, has already shown >90% tumor inhibition in preclinical models with synergy alongside anti-PD-1 checkpoint inhibitors.
Targeting first patient dosing in Q1 2026, the company is aligning a Web3-native, globally accessible financing model with a traditional clinical pathway. ATON stands out as the only Nasdaq-listed name combining digital assets with a cancer pipeline, offering exposure to both biotech and blockchain upside. This one could be an afterhours headline magnet.
TransCode Therapeutics (NASDAQ:RNAZ) is ripping higher after acquiring Polynoma LLC, adding seviprotimut-L, a Phase 3-ready melanoma vaccine, along with a $25M equity investment from CK Life Sciences. The transaction arms TransCode with both late-stage immuno-oncology and the funds to advance TTX-MC138, its flagship microRNA therapy, into Phase 2 trials for metastatic cancers.
New CEO Dr. Philippe Calais brings leadership continuity, while new board member Elizabeth Czerepak adds seasoned oversight. With the potential for cross-platform synergies and a now-loaded pipeline, RNAZ could carry momentum into the post-market session.
Stoke Therapeutics (NASDAQ:STOK) is getting quiet accumulation after recent coverage highlighted its Phase 1/2a MONARCH data in Dravet syndrome, a severe form of childhood epilepsy. While not making headlines today, STOK remains a top biotech sleeper, especially with additional data readouts expected in Q4. Investors should keep this on the radar for afterhours commentary or insider buying signals.
American Rebel (NASDAQ:AREB), known for its personal safes and Second Amendment-focused branding, is one of the day’s stealth risers amid growing attention to its new distribution partnerships and planned product line expansion.
Kyverna Therapeutics (NASDAQ:KYTX) is drawing speculative interest due to its progress on KYV-101, an autologous CAR T-cell therapy for lupus nephritis and other autoimmune diseases. Phase 1 data is expected later this quarter, and whispers of early efficacy are already circulating among biotech desks. If a data drop or trial update hits afterhours, KYTX could gap up fast.
Acurx Pharmaceuticals (NASDAQ:ACXP) focuses on developing non-traditional antibiotics to combat antimicrobial resistance, a space that’s heating up as regulators and public health authorities sound alarms. Any signal around enrollment progress, Fast Track designation, or new data from its Phase 2 trials could attract capital into the name. Low float and high upside make ACXP a stealth candidate into the afterhours.
Diginex (NASDAQ:EQOS), though quiet today, may reemerge if crypto volatility resumes. With its roots in digital asset exchange infrastructure, EQOS offers traders a play on crypto sentiment and tokenized finance themes and, if news breaks around blockchain compliance or product expansion, the stock could spike afterhours on limited liquidity.
ioneer (NASDAQ:IONR), a developer of lithium-boron projects in Nevada, is in the spotlight amid policy chatter about domestic critical minerals production. With the Rhyolite Ridge project on the DOE’s radar, any permitting progress or offtake announcements could move the stock into the evening hours. One to monitor if energy names catch a macro bid late in the session.
Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.
For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
About Venu Holding Corporation
Venu Holding Corporation (NYSE American:VENU) is redefining the live entertainment landscape through a national network of premium amphitheaters powered by its Luxe FireSuites model. With partnerships like AEG and Aramark, and an active development pipeline of over $5 billion (including $1 billion underway), Venu is building the next generation of destination venues, where investors, fans, and artists come together in a hospitality-first experience.
Through its innovative 40/40/20 financing model and integrated hospitality campuses, the company is building a national network of premium amphitheaters and entertainment destinations, targeting 40 venues by 2030. Its flagship Ford Amphitheater was nominated as Pollstar’s Best New Venue of 2024.
24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
CONTACT:
24/7 Market News
Editor@247marketnews.com